Research Reports | Market Assessment
January 2014

Prostate Cancer | Pharmacor | G7 | 2014

Last Updated 13 December 2013
The prostate cancer market has witnessed considerable changes over the last three years, owing to the launch of five new therapies for treatment of metastatic castrate-resistant prostate cancer (mCRPC). Abiraterone (Johnson & Johnson/Janssen Biotech/Janssen-Cilag’s Zytiga), initially approved for mCRPC patients who have received prior treatment with docetaxel (Sanofi’s Taxotere, generics), is gaining widespread use in the commercially lucrative chemotherapy-naive setting, following its label extension in the United States and Europe. Enzalutamide (Medivation/Astellas Pharma’s Xtandi) launched in 2012 in the United States and 2013 in Europe, follows abiraterone and promises to compete fiercely for a share of the mCRPC market. The expected launch of several emerging therapies for prostate cancer over the next decade will heighten the competition, and it will be imperative for current and emerging therapies to differentiate and position themselves to maximize clinical and commercial success.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports